<p><strong>Agents Inducing CYP3A Metabolism</strong>: Concomitant administration of Imatinib and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents.<br />
<br />
<strong>Agents Inhibiting CYP3A Metabolism</strong>: Concomitant administration of Imatinib and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase. Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice).<br />
<br />
<strong>Interactions with Drugs Metabolized by CYP3A4</strong>: Imatinib will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Imatinib with CYP3A4 substrates that have a narrow therapeutic window. Because warfarin is metabolized by CYP2C9 and CYP3A4, use low-molecular weight or standard heparin instead of warfarin in patients who require anticoagulation.<br />
<br />
<strong>Interactions with Drugs Metabolized by CYP2D6</strong>: Use caution when administering Imatinib with CYP2D6 substrates that have a narrow therapeutic window.</p>